Dear Fellow Shareholder:
I’m delighted to present Immutep’s annual report for the
financial year 2022.
Immutep continued to forge its leadership role in the
emerging LAG-3 landscape throughout a year that saw
increasing attention from industry on this exciting new
immune checkpoint. As a global biotech developing
immunotherapeutic products for cancer and autoimmune
disease, we have more product candidates and programs
focused on LAG-3 than any other drug development
company and we have retained our status of being the only
LAG-3 pure play.
For more information, download the attached PDF.
Download this document
